For example, the lncRNA FOXD3-AS1 has been demonstrated to promote aggressive traits in thyroid cancer by altering the TGF-β1/Smads pathway; FOXD3-AS1 depletion inhibits EMT and tumor progression through inactivation of the TGF-β signaling pathway by upregulation of miR-296-5p [75]. This evidence concerns the gene FOXD3 and neoplasm.